Literature DB >> 28695915

Targeted therapies: Lenvatinib SELECTs survival benefit.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28695915     DOI： 10.1038/nrclinonc.2017.103

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.

Authors:  Marcia S Brose; Francis P Worden; Kate L Newbold; Matthew Guo; Arti Hurria
Journal:  J Clin Oncol       Date:  2017-06-14       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.